(NASDAQ: JANX) Janux Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.
Janux Therapeutics's earnings in 2026 is -$101,895,000.On average, 19 Wall Street analysts forecast JANX's earnings for 2026 to be -$178,350,277, with the lowest JANX earnings forecast at -$271,146,314, and the highest JANX earnings forecast at -$147,783,162. On average, 16 Wall Street analysts forecast JANX's earnings for 2027 to be -$228,970,672, with the lowest JANX earnings forecast at -$351,311,311, and the highest JANX earnings forecast at -$173,676,793.
In 2028, JANX is forecast to generate -$242,257,322 in earnings, with the lowest earnings forecast at -$358,384,693 and the highest earnings forecast at -$66,944,509.